Kos, Barr Settle Niaspan Patent Litigation With Unusual Deal

Law360, New York (April 13, 2005, 12:00 AM EDT) -- Barr Pharmaceuticals Inc. and Kos Pharmaceuticals Inc. have penned an unusual settlement agreement to put an end to their patent litigation over Kos' cholesterol lowering drugs Niaspan and Advicor, the two companies said Wednesday.

Under the seven-year deal, Barr subsidiary Duramed Pharmaceuticals will co-promote Niaspan and Advicor -- as well as any future dosages or modified versions -- to obstetricians, gynecologists and other women's healthcare practitioners in exchange for royalties on quarterly and yearly sales.

Kos will help train a Duramed sales force of 40 to...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.